Israel
· Delayed Price · Currency is ILS · Price in ILA Oramed Pharmaceuticals Statistics
Total Valuation
TLV:ORMP has a market cap or net worth of ILS 308.94 million. The enterprise value is -202.34 million.
| Market Cap | 308.94M |
| Enterprise Value | -202.34M |
Important Dates
The next estimated earnings date is Friday, March 7, 2025.
| Earnings Date | Mar 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +2.51% |
| Shares Change (QoQ) | -1.67% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 31.97M |
Valuation Ratios
The trailing PE ratio is 18.61.
| PE Ratio | 18.61 |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | 0.53 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -12.19 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 6.86 |
Financial Position
The company has a current ratio of 27.08, with a Debt / Equity ratio of 0.00.
| Current Ratio | 27.08 |
| Quick Ratio | 26.99 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.05 |
| Interest Coverage | -6.33 |
Financial Efficiency
Return on equity (ROE) is 2.89% and return on invested capital (ROIC) is -4.29%.
| Return on Equity (ROE) | 2.89% |
| Return on Assets (ROA) | -4.12% |
| Return on Invested Capital (ROIC) | -4.29% |
| Return on Capital Employed (ROCE) | -8.17% |
| Revenue Per Employee | n/a |
| Profits Per Employee | 4.15M |
| Employee Count | 4 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -24.77% in the last 52 weeks. The beta is 1.66, so TLV:ORMP's price volatility has been higher than the market average.
| Beta (5Y) | 1.66 |
| 52-Week Price Change | -24.77% |
| 50-Day Moving Average | 840.33 |
| 200-Day Moving Average | 873.06 |
| Relative Strength Index (RSI) | 47.83 |
| Average Volume (20 Days) | 37,787 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.78 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -48.56M |
| Pretax Income | 26.61M |
| Net Income | 16.60M |
| EBITDA | -47.76M |
| EBIT | -48.56M |
| Earnings Per Share (EPS) | 0.41 |
Balance Sheet
The company has 528.97 million in cash and 1.59 million in debt, giving a net cash position of 529.78 million.
| Cash & Cash Equivalents | 528.97M |
| Total Debt | 1.59M |
| Net Cash | 529.78M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 578.12M |
| Book Value Per Share | 14.46 |
| Working Capital | 511.13M |
Cash Flow
In the last 12 months, operating cash flow was -29.44 million and capital expenditures -37,173, giving a free cash flow of -29.47 million.
| Operating Cash Flow | -29.44M |
| Capital Expenditures | -37,173 |
| Free Cash Flow | -29.47M |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
TLV:ORMP does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.51% |
| Shareholder Yield | -2.51% |
| Earnings Yield | 5.37% |
| FCF Yield | -9.54% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
TLV:ORMP has an Altman Z-Score of 5.51.
| Altman Z-Score | 5.51 |
| Piotroski F-Score | n/a |